Checkmate Pharmaceuticals Inc (CMPI) Stock
CMPI is no longer traded. Checkmate Pharmaceuticals was delisted from the Nasdaq in May 2022.
Prices on this page are historical; the last trade was May 27, 2022 at $10.50.
Checkmate Pharmaceuticals stock price history
CMPI final trading statistics
- Final close
- $10.50
- Final trading day
- May 27, 2022
- Market cap at delisting
- $231.40M
- Shares outstanding
- 22.04M
- Final 52-week range
- $2.00 – $10.50
- Avg. volume (final 3 mo.)
- 217,061
- All-time high (split-adj.)
- $17.62 · Dec 2020
- All-time low (split-adj.)
- $2.02 · Jan 2022
- Return since IPO
- -25.0%
- Beta
- —
- Book value / share
- $2.54
- Price / book
- 4.13
Checkmate Pharmaceuticals annual financials
| Fiscal year | Revenue | Net income | EPS |
|---|---|---|---|
| FY2021 | $0.00 | -$61.4M | -$2.84 |
| FY2020 | $0.00 | -$36.9M | -$8.84 |
| FY2019 | $0.00 | -$28.3M | — |
| FY2018 | $0.00 | -$20.8M | — |
Last five fiscal years reported before the delisting; fiscal year ending December. EPS is adjusted (non-GAAP) EPS as reported. Source: company filings via EODHD.
About Checkmate Pharmaceuticals Inc
Checkmate Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing novel therapeutics for the treatment of cancer. It develops CMP-001, which is in phase II clinical trial in combination with pembrolizumab to treat patients with PD-1 refractory melanoma; combination with nivolumab to treat patients with PD-1 naïve neoadjuvant melanoma; and treatment in patients with PD-1 refractory melanoma. Checkmate Pharmaceuticals, Inc. has strategic alliances with Merck KGaA and Pfizer. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts. As of May 27, 2022, Checkmate Pharmaceuticals, Inc. operates as a subsidiary of Regeneron Pharmaceuticals, Inc.
Checkmate Pharmaceuticals stock FAQ
What happened to Checkmate Pharmaceuticals stock?
Checkmate Pharmaceuticals stock was delisted from the Nasdaq. Its final close was $10.50 on May 27, 2022.
Is CMPI stock still trading?
No. CMPI was delisted from the Nasdaq in May 2022 and no longer trades on a U.S. exchange.
What was the last price of CMPI stock?
CMPI closed at $10.50 on its final trading day, May 27, 2022, for a market value of about $231.40M.
What were Checkmate Pharmaceuticals's revenue and earnings in its last full fiscal year?
Checkmate Pharmaceuticals reported revenue of $0.00 and net income of -$61.4M in fiscal 2021, its last full year as a public company.
When did Checkmate Pharmaceuticals go public?
Checkmate Pharmaceuticals Inc stock began trading on August 7, 2020.